Literature DB >> 35095135

Late-onset Ocular Toxicity Presenting as Uveitis Caused by Crizotinib.

Megumi Iseki1, Toshikatsu Kaburaki1, Makoto Aihara1, Hiromasa Sawamura1.   

Abstract

A 64-year-old female suffering from lung cancer was treated with crizotinib. Two years later, whitish massive optic disc oedema was observed in the right eye. The fluorescein angiography results were suggestive of uveitis but also revealed leakage from the optic disc, retinal veins, and capillaries in the posterior retina and the periphery. These findings remained for over a year without deterioration of vision and disappeared immediately after crizotinib was replaced with alectinib. Late-onset ocular toxicity by crizotinib was strongly suspected, given the clinical course. This is the first report precisely documenting crizotinib-induced morphological changes in the optic disc and retina.
© 2021 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Crizotinib; ocular toxicity; optic disc oedema; vasculitis

Year:  2021        PMID: 35095135      PMCID: PMC8794249          DOI: 10.1080/01658107.2021.1876099

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  18 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.

Authors:  Stephen G Chun; Puneeth Iyengar; David E Gerber; Robert N Hogan; Robert D Timmerman
Journal:  J Clin Oncol       Date:  2014-03-10       Impact factor: 44.544

3.  Imaging of localized retinal nerve fiber layer defects in preperimetric glaucoma using spectral-domain optical coherence tomography.

Authors:  Masayuki Nukada; Masanori Hangai; Satoshi Mori; Kohei Takayama; Noriko Nakano; Satoshi Morooka; Hanako O Ikeda; Tadamichi Akagi; Atsushi Nonaka; Nagahisa Yoshimura
Journal:  J Glaucoma       Date:  2014-03       Impact factor: 2.503

Review 4.  Ocular toxicity associated with systemic drug therapy.

Authors:  R S Moorthy; S Valluri
Journal:  Curr Opin Ophthalmol       Date:  1999-12       Impact factor: 3.761

5.  Case of metastatic pulmonary carcinoma in optic disc diagnosed from results of biopsy performed during vitrectomy surgery.

Authors:  Reina Fukuda; Tatsuro Tanabe; Hiromasa Sawamura; Mikiko Kawata; Hideki Tsuji; Toshikatsu Kaburaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-16       Impact factor: 3.117

Review 6.  Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Authors:  Federico Cappuzzo; Denis Moro-Sibilot; Oliver Gautschi; Ekaterini Boleti; Enriqueta Felip; Harry J M Groen; Paul Germonpré; Peter Meldgaard; Edurne Arriola; Nicola Steele; Jesme Fox; Patrick Schnell; Arne Engelsberg; Jürgen Wolf
Journal:  Lung Cancer       Date:  2014-12-18       Impact factor: 5.705

7.  FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

Authors:  Dickran Kazandjian; Gideon M Blumenthal; Huan-Yu Chen; Kun He; Mona Patel; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2014-08-28

Review 8.  Drug-induced uveitis.

Authors:  R S Moorthy; S Valluri; L M Jampol
Journal:  Surv Ophthalmol       Date:  1998 May-Jun       Impact factor: 6.048

9.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

10.  Drug-induced uveitis.

Authors:  Nikolas Js London; Sunir J Garg; Ramana S Moorthy; Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.